{"id":958106,"date":"2026-05-05T07:44:54","date_gmt":"2026-05-05T11:44:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/"},"modified":"2026-05-05T07:44:54","modified_gmt":"2026-05-05T11:44:54","slug":"bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/","title":{"rendered":"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE"},"content":{"rendered":"
\n

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting.<\/p>\n

\n
\n Oral Presentations:<\/u>
\n <\/strong>
\n
\n Encaleret\u00a0Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE Trial<\/strong>
\n
\n Presenter: <\/strong>Filomena Cetani, M.D., Ph.D., University of Pisa, IT
Date & Time:<\/strong> Tuesday, May 12 at 11:50 am CEST<\/p>\n

\n Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-Function <\/strong>
\n
\n CASR<\/em>
\n <\/strong>
\n Variants as the Most Common Genetic Cause Identified<\/strong>
\n
\n Presenter: <\/strong>Arun Mathew, BridgeBio Endocrinology, U.S.
Date & Time:<\/strong> Tuesday, May 12 at 12:20 pm CEST<\/p>\n

\n
\n Poster:<\/u>
\n <\/strong>
\n
\n Autosomal Dominant Hypocalcemia Type 1 and Type 2: Baseline Quality of Life Measures in Adult Participants in the CLARIFY Disease Monitoring Study<\/strong>
\n
\n Presenter: <\/strong>Heide Siggelkow, M.D., University Medical Center of G\u00f6ttingen, DE
Poster ID: <\/strong>P72
Date & Time:<\/strong> Sunday, May 10 at 4:55 pm CEST and Monday, May 11 at 5 pm CEST<\/p>\n

\n
\n ePoster:<\/u>
\n <\/strong>
\n
\n Epidemiology and Clinical Management of ADH1: A Systematic Literature Review<\/strong>
\n
\n Presenter: <\/strong>Arun Mathew, BridgeBio Endocrinology, U.S.
Poster ID:<\/strong> EP260<\/p>\n

\n About BridgeBio<\/strong>
\n
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com<\/strong><\/a> and follow us on LinkedIn<\/strong><\/a>, X<\/strong><\/a>, Facebook<\/strong><\/a>, Instagram<\/strong><\/a>, YouTube<\/strong><\/a>, and TikTok<\/strong><\/a>.<\/p>\n

\n BridgeBio Media Contact:<\/strong>
\n
Bubba Murarka, Executive Vice President
contact@bridgebio.com<\/a>\u00a0\u00a0
(650)-789-8220<\/p>\n

\n BridgeBio Investor Contact:<\/strong>
\n
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting. Oral Presentations: Encaleret\u00a0Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE Trial Presenter: Filomena Cetani, M.D., Ph.D., University of Pisa, ITDate & Time: Tuesday, May … <\/p>\n

Continue reading “BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958106","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting. Oral Presentations: Encaleret\u00a0Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE Trial Presenter: Filomena Cetani, M.D., Ph.D., University of Pisa, ITDate & Time: Tuesday, May … Continue reading "BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-05T11:44:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE\",\"datePublished\":\"2026-05-05T11:44:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/\"},\"wordCount\":368,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/\",\"name\":\"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=\",\"datePublished\":\"2026-05-05T11:44:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Market Newsdesk","og_description":"PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting. Oral Presentations: Encaleret\u00a0Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE Trial Presenter: Filomena Cetani, M.D., Ph.D., University of Pisa, ITDate & Time: Tuesday, May … Continue reading \"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-05T11:44:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE","datePublished":"2026-05-05T11:44:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/"},"wordCount":368,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/","name":"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=","datePublished":"2026-05-05T11:44:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjcwNiM3NTgxNDY3IzIxNTY5MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958106"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958106\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}